Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC.

19 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Previous flu infections can reduce the severity of H1N1

Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease.

18 Nov 2009

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.

18 Nov 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials.

From Parexel 17 Nov 2009

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao.

17 Nov 2009

Phase II clinical study to evaluate Nanocort commenced

Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments.

17 Nov 2009

Cold weather can trigger Raynaud's disease

Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack.

17 Nov 2009

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Targeted Genetics Corporation today announced its financial results for the third quarter ended September 30, 2009.

17 Nov 2009

Live Facebook chat on H1N1 flu

People who have questions about the H1N1 flu can get answers from infectious disease experts at Rush University Medical Center during a one-hour, live Facebook chat to be held on Friday, November 20 from12 p.m. until 1 p.m.

16 Nov 2009

4SC raises funds for further development of its current product pipeline

4SC AG, a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009.

16 Nov 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

VisEn Medical launches two new agents for imaging quantification

Study: EP4 agonist may reduce gastric bleeding and inflammation

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Previous flu infections can reduce the severity of H1N1

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

Phase II clinical study to evaluate Nanocort commenced

Cold weather can trigger Raynaud's disease

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Live Facebook chat on H1N1 flu

4SC raises funds for further development of its current product pipeline

EntreMed announces financial results for the third quarter of 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Spine Care Institute established by Hospital for Special Surgery

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in